secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001370053-23-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Q2 net loss $39.8M; imsidolimab Phase 3 enrollment complete
----------------------------------------------------------------------

- Q2 net loss $39.8M ($1.50/sh) vs $32.6M ($1.15) YoY; six-month loss $84.1M ($3.08/sh).
- Completed enrollment of GEMINI-1 Phase 3 for imsidolimab in GPP; top-line data expected Q4 2023.
- Cash and investments $488.7M at June 30; updated year-end 2023 guidance $380-395M; runway through 2026.
- Initiating global Phase 2b for rosnilimab in RA in Q3 2023; second Phase 2 trial by year-end.
- Daniel Faga appointed permanent president and CEO; new SAB members added.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000048/0001370053-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000048/anab-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer